Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zavegepant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL known ✓ | Q16602 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CALCA | P06881 | 16/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zavegepant SCHEMBL23748834 | 1.00 | CALCRL (1.00) | CALCRLCYP3A4CALCA | |
| Zavegepant SCHEMBL107428 | 1.00 | CALCRL (1.00) | CALCRLCYP3A4CALCA | |
| Zavegepant SCHEMBL29918913 | 1.00 | CALCRL (1.00) | CALCRLCYP3A4CALCA | |
| Zavegepant SCHEMBL142472 | 1.00 | CALCRL (1.00) | CALCRLCYP3A4CALCA | |
| Zavegepant SCHEMBL29182146 | 0.99 | CALCRL (0.99) | CALCRLCYP3A4CALCA | |
| Zavegepant SCHEMBL29918668 | 0.99 | CALCRL (0.99) | CALCRLCYP3A4CALCA | |
| SCHEMBL30763651 | 0.97 | CALCRL (0.95) | CALCRLCYP3A4CALCA | |
| SCHEMBL29161729 | 0.97 | CALCRL (0.95) | CALCRLCYP3A4CALCA | |
| SCHEMBL29161731 | 0.97 | CALCRL (0.95) | CALCRLCYP3A4CALCA | |
| SCHEMBL178848 | 0.93 | CALCRL (0.88) | CALCRLCYP3A4CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 327 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130901-A1 | CGRP RECEPTOR ANTAGONIST FOR THE TREATMENT OF MIGRAINE | ALLERGAN PHARMACEUTICALS INT LTD (IE) | 2026-05-14 | — | — | US | claimed |
| US-12622968-B2 | Formulation for oral delivery of proteins, peptides and small molecules with poor permeability | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2026-05-12 | — | — | US | claimed |
| WO-2026090164-A1 | COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN | KALLYOPE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4719347-A1 | SPRAY-DRIED COMPOSITIONS COMPRISING CGRP RECEPTOR ANTAGONISTS | Orexo AB (SE) | 2026-04-08 | — | — | EP | claimed |
| US-20260091031-A1 | CGRP RECEPTOR ANTAGONISTS FOR TREATING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) | CHIARUGI ALBERTO (IT) | 2026-04-02 | — | — | US | claimed |
| EP-4698530-A1 | NK3 MODULATORS AND USES THEREOF | Kallyope, Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| US-20260001944-A1 | METHODS OF TREATING PAIN CAUSED BY A BONE FRACTURE | UNIV INDIANA TRUSTEES (US) | 2026-01-01 | — | — | US | claimed |
| US-20250276959-A1 | SOLID STATE FORMS OF ZAVEGEPANT HYDROCHLORIDE AND PROCESS FOR PREPARATION THEREOF | TEVA CZECH INDUSTRIES S.R.O. | 2025-09-04 | — | — | US | claimed |
| EP-4587023-A1 | CGRP RECEPTOR ANTAGONISTS FOR TREATING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) | Chiarugi, Alberto (IT) | 2025-07-23 | — | — | EP | claimed |
| WO-2025125353-A1 | METHOD OF PREPARATION OF ZAVEGEPANT, SYNTHESIS INTERMEDIATES OF ZAVEGEPANT AND METHODS OF PREPARATION THEREOF | MOEHS IBERICA, S.L. (ES) | 2025-06-19 | — | — | WO | claimed |
| WO-2022271604-A1 | METHOD OF TREATING A PATIENT INFECTED WITH A CORONAVIRUS AND HAVING A BASELINE LEVEL OF CRP BELOW 150 MG/L | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-12-29 | — | — | WO | claimed |
| US-20220401439-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2022-12-22 | — | — | US | claimed |
| EP-4076395-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2022-10-26 | — | — | EP | claimed |
| WO-2022217008-A1 | SOLID STATE FORMS OF ZAVEGEPANT AND PROCESS FOR PREPARATION THEREOF | TEVA CZECH INDUSTRIES S.R.O (CZ) | 2022-10-13 | — | — | WO | claimed |
| WO-2022185224-A1 | TREATMENT AND/OR REDUCTION OF OCCURRENCE OF MIGRAINE | HASLETON MARK (IL) | 2022-09-09 | — | — | WO | claimed |
| CN-114980862-A | Intranasal pharmaceutical compositions of CGRP inhibitors | 拜尔哈文制药股份有限公司 | 2022-08-30 | — | — | CN | claimed |
| US-20220249468-A1 | FORMULATION FOR ORAL DELIVERY OF PROTEINS, PEPTIDES AND SMALL MOLECULES WITH POOR PERMEABILITY | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-08-11 | — | — | US | claimed |
| WO-2022165291-A1 | PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS AND METHODS OF THEIR USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-08-04 | — | — | WO | claimed |
| WO-2022132989-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-06-23 | — | — | WO | claimed |
| WO-2022109077-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-05-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622968-B2 | Formulation for oral delivery of proteins, peptides and small molecules with poor permeability | CETP, LIPA, TAS2R40 | CALCRL 22/4885CYP3A4 3279/4885CALCA 63/4885 |
| US-20260001944-A1 | METHODS OF TREATING PAIN CAUSED BY A BONE FRACTURE | OPRL1, CALCRL, OPRK1 | CALCRL 2/4885CYP3A4 1457/4885CALCA 5/4885 |
| US-20220401439-A1 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | CALCA, CALCB, CALCRL | CALCRL 3/4885CYP3A4 3577/4885CALCA 1/4885 |
| US-20260091031-A1 | CGRP RECEPTOR ANTAGONISTS FOR TREATING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) | CALCRL, GRPR, OPRL1 | CALCRL 1/4885CYP3A4 1969/4885CALCA 5/4885 |
| US-20220249468-A1 | FORMULATION FOR ORAL DELIVERY OF PROTEINS, PEPTIDES AND SMALL MOLECULES WITH POOR PERMEABILITY | CETP, LIPA, PNLIP | CALCRL 10/4885CYP3A4 4246/4885CALCA 15/4885 |
| US-20250276959-A1 | SOLID STATE FORMS OF ZAVEGEPANT HYDROCHLORIDE AND PROCESS FOR PREPARATION THEREOF | PIGT, VKORC1, NAMPT | CALCRL 3809/4885CYP3A4 37/4885CALCA 4254/4885 |
| US-20260130901-A1 | CGRP RECEPTOR ANTAGONIST FOR THE TREATMENT OF MIGRAINE | PTGDR, GRPR, CALCRL | CALCRL 3/4885CYP3A4 3727/4885CALCA 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.